This proposal, """"""""Clinical and molecular studies of novel therapeutics in malignant brain tumors"""""""", builds upon my experience conducting productive, patient-oriented, neuro-oncology research and serving as the primary mentor for 9 trainees over the past 9 years at the Massachusetts General Hospital. The focus of this award is to develop improved treatment for patients with glioblastoma, a uniformly fatal cancer. The award would enable me to secure protected time and resources for research and mentoring and would enable me to expand my NIH-funded research program to develop new clinical trials of molecularly-targeted agents with novel molecular and imaging endpoints. These studies would build upon existing, funded, phase 2 trials with the goal of targeting multiple molecular pathways in glioblastoma. New research proposed in the application targets the PI3K/Akt/mTOR cell signaling pathway and the VEGFR-mediated angiogenesis cascade in an effort to improve outcome in glioblastoma patients. I have been able to establish an outstanding research environment in which to conduct these studies. Resources include a comprehensive, longitudinal, electronic IRB-approved, patient research database linked to a brain tumor tissue bank; a pipeline of novel agents from the NCI and industry; an extensive support infrastructure for clinical trials/research; an outstanding group of well-funded, productive, senior collaborators; a large brain tumor patient population; an expanding pool of talented research fellows and an institutional K12 training grant in neuro-oncology. Through better coordination of the clinical research program; more time to develop new studies with novel endpoints and more time to mentor neuro-oncology trainees this award will enhance my career as a clinical investigator, expand my grant support and enable me to produce trainee graduates who are poised to secure their own grant support for productive careers in patient-oriented neuro-oncology research. ? ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA125440-02
Application #
7476400
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
2007-08-01
Project End
2012-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
2
Fiscal Year
2008
Total Cost
$187,934
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Han, Catherine H; Batchelor, Tracy T (2017) Primary Central Nervous System Lymphoma. Continuum (Minneap Minn) 23:1601-1618
Yáñez, M Loreto; Miller, Julie J; Batchelor, Tracy T (2017) Diagnosis and treatment of epidural metastases. Cancer 123:1106-1114
Tateishi, Kensuke; Higuchi, Fumi; Miller, Julie J et al. (2017) The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res 77:4102-4115
Wang, Nancy; Jain, Rakesh K; Batchelor, Tracy T (2017) New Directions in Anti-Angiogenic Therapy for Glioblastoma. Neurotherapeutics 14:321-332
Arrillaga-Romany, Isabel; Chi, Andrew S; Allen, Joshua E et al. (2017) A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 8:79298-79304
Ellingson, Benjamin M; Gerstner, Elizabeth R; Smits, Marion et al. (2017) Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res 23:5745-5756
Andronesi, Ovidiu C; Esmaeili, Morteza; Borra, Ronald J H et al. (2017) Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol 1:
Tateishi, Kensuke; Iafrate, A John; Ho, Quan et al. (2016) Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22:4452-65
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Andronesi, Ovidiu C; Loebel, Franziska; Bogner, Wolfgang et al. (2016) Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res 22:1632-41

Showing the most recent 10 out of 62 publications